Apogee Therapeutics, Inc. (APGE)

Market Cap	6.81B +229.2%
Revenue (ttm)	n/a
Net Income	-255.84M
EPS	-4.22
Shares Out	73.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,229,251
Open	92.25
Previous Close	90.55
Day's Range	91.23 - 95.32
52-Week Range	31.60 - 95.32
Beta	1.02
Analysts	Strong Buy
Price Target	109.67 (+18.95%)
Earnings Date	May 11, 2026

About APGE

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 261
• Stock Exchange: NASDAQ
• Ticker Symbol: APGE
• Website: https://www.apogeetherapeutics.com

Analyst Summary

According to 13 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price target is $109.67, which is an increase of 18.95% from the latest price.

Price Target

$109.67

(18.95% upside)

Analyst Consensus: Strong Buy